DaRui Bio Announces Over RMB 100 Million Pre-B Financing to Advance siRNA Therapeutics and Files IPO Prospectus

Mar 15, 2025 12:53 CST Updated 12:53

Rona Therapeutics

Nucleic Acid Drug Developer

On March 14, 2025, Rona Therapeutics (Shanghai) Co., Ltd. ("Rona Therapeutics") announced the successful completion of its Pre-B round of financing, raising US$25 million (approximately RMB 180 million).This round of financing was led by Guanghua Wutong, with new and existing shareholders such as Lilly Asia Ventures, Jiangyuan Investment, and Boyuan Capital participating. This fully demonstrates the continued recognition and confidence in Rona Therapeutics' innovation in the nucleic acid drug field.

This round of financing will help Rona Therapeutics advance its unique delivery and chemical modification platform technologies, further expand its siRNA clinical pipeline in cardiovascular metabolism, weight loss, and other fields, and comprehensively enhance its large-scale production capabilities. The successful completion of this financing round is attributed to the breakthrough progress achieved by Rona Therapeutics in several key milestones, including the rapid advancement of its clinical pipeline and significant achievements in preclinical studies. These developments not only validate the technological advantages of the company's innovative platform but also fully demonstrate its tremendous clinical potential in treating major diseases.

CEO of Rona Therapeutics

Co-Founder

Stella SHI

We are deeply honored to have received strong support from Guanghua Phoenix and both new and existing shareholders. This round of financing will provide us with powerful momentum to accelerate our R&D progress and push the boundaries of technology, enabling us to bring more innovative and groundbreaking siRNA therapies to patients with unmet clinical needs worldwide.

Since its establishment in 2021, Rona Therapeutics has rapidly become a leader in the siRNA therapeutics field with its modular and programmable delivery and chemical modification platform. The company is committed to addressing complex diseases such as hypercholesterolemia and hypertriglyceridemia, focusing on advancing human health through cutting-edge technology. This Pre-B round of financing will provide strong support for Rona Therapeutics to accelerate clinical research and further the development of extrahepatic delivery systems, reinforcing its leading position in the global small nucleic acid drug sector.

About Guanghua Phoenix

Chengdu Guanghua Phoenix Equity Investment Fund Management Co., Ltd. is located in Wenjiang District, Chengdu City, and is mainly engaged in the operation of government industrial investment funds and market-oriented fund investment management. The company adheres to the business philosophy of focus, professionalism, and sincerity, accurately deploying its fund ecosystem around a "FOF + direct investment" strategy. Through continuous meticulous efforts and efficient investments, it aims to empower industrial development. Currently, the company manages approximately 9 billion yuan in assets and has collaborated with leading enterprises, listed companies, investment institutions, and other partners to establish more than 20 investment funds with a total scale exceeding 46 billion yuan, covering all stages of a company's lifecycle. As one of the key investment areas for Guanghua Phoenix Fund, healthcare has seen investments in several high-growth and breakthrough technology innovative drug companies and high-end medical device enterprises such as Kelun-Biotech (HK.06990), Fulllink Technology, Toray Biology, MicroZell Biology, Jinjiang Electronics, and Haijieya Medical, accumulating rich industry resources.

About Rona Therapeutics

Rona Therapeutics is a global leading nucleic acid innovative drug platform company, focusing on the treatment of metabolic diseases, weight loss, and other related conditions. Rona Therapeutics is committed to developing best-in-class and first-in-industry siRNA drugs with differentiation and innovation to address unmet clinical needs and improve treatment outcomes for cardiovascular diseases, obesity, and metabolic dysfunction-associated steatohepatitis (MASLD), among others. Additionally, Rona Therapeutics is actively unlocking the significant potential of extrahepatic delivery technologies, such as fat and muscle delivery, for the treatment of various metabolic syndromes.

E.N.D

Previous article recommendations:(Click on the article title below to open the original text)

China's National Medical Products Administration Approves First Mesenchymal Stromal Cell Drug for Clinical Use

China's First CIK Cell Therapy Commercialization Imminent! Yantai Biotech’s Solid Tumor Cell Therapy Proposed for Priority Review

China's First Case of Autism Stem Cell New Drug Approved for Clinical Trials

Gene therapy company Huayi Lejian, founded by Rao Yi, officially launches Phase III clinical trial for its first AAV gene drug

Hainan Makes Another Bold Move! Breaking the Bottleneck in the Industrialization of Stem Cell Exosomes, Check Out the Black Technology in China-produced Exosome Processes

A Biotechnology Industrial Park Project in China Breaks Ground with a Total Investment of 1 Billion Yuan, Nearly 200,000 Square Meters of Total Construction Area, Focusing on Stem Cell and Regenerative Medicine, Biopharmaceutical CXO, and Other Fields

The World's First Circular RNA Therapy Approved by the FDA for Clinical Trials Completes First Patient Dosing!

749 Million Yuan! The Full-Year Sales of the First Solid Tumor Cell Therapy Announced

A Gene Therapy Company in China Completes Over 100 Million Yuan in Pre-A Round Financing

iPSC-Derived Corneal Cell Therapy Breaks Through Clinical Bottlenecks, Bringing Hope to Tens of Millions of Patients Worldwide

A Chinese company focused on the exosome field has completed a nearly 100-million-yuan Series A financing.

Sichuan Releases Stem Cell Local Standards for the First Time

Shanghai Children's Medical Center Successfully Completes First Batch of Gene Therapy for Duchenne Muscular Dystrophy

Another Leading Company Expands into Cell and Gene Therapy, CGT Sector in China Shows Signs of Recovery

Priced at Over Ten Million, the Logic Behind the "Astronomical" Cost of the First Mesenchymal Stem Cell Therapy in the U.S.

Over 700 Million Yuan! ByteDance Establishes New Company to Accelerate Layout in Cell Therapy and High-End Hospital Construction

Two Hospitals in China Successfully Obtain "Dual Approval" for Stem Cell Clinical Projects

$100 Million! A Gene Therapy Company Acquired

A 60,000-square-meter hospital in China exclusively dedicated to cell therapy has officially opened.

FDA Approves First Induced Pluripotent Stem Cell (iPSC) Therapy for Phase III Clinical Trial

FDA Accepts First-ever IND for Regulatory T-cell (Treg) Therapy to Treat ALS Globally

The Cell Therapy Center of Huaxi Licheng Hospital Officially Put into Use, Received the First Batch of Patients in February

Statement:Content sourced from the company's official channels, This article aims at knowledge sharing. All content is for reference only and does not constitute any advice.